ClinicalTrials.gg

Program

Aspirin

Also written as “dabigatran with ASA”, “ASA” and “Acetylsalicylic acid (Aspirin, BAY1019036)”.

Its studies are mostly in Coronary Artery Disease · Cardiovascular Diseases · Common Cold · Thrombosis · Peptic Ulcer, led by 28 companies.

Furthest: phase 4, since Dec 15, 200970 company-led studies, 3 open or runningNext primary completion: Mar 10, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayer211 open or runningphase 4since Dec 15, 2009Jul 12, 2007Mar 10, 2027phase 1 · NCT07652723
Boehringer Ingelheim60 open or runningphase 4since Aug 10, 2005Aug 10, 2005none ahead
Bristol-Myers Squibb50 open or runningphase 1since Jul 8, 2009Jul 8, 2009none ahead
Abbott30 open or runningphase 3since Feb 21, 2008Feb 21, 2008none ahead
Boston Scientific30 open or runningphase 4since May 1, 2012Dec 21, 2011none ahead
Johnson & Johnson30 open or runningphase 4since Dec 2, 2005Dec 2, 2005none ahead
Aralez Pharmaceuticals20 open or runningphase 1since Feb 27, 2007Feb 27, 2007none ahead
Astellas Pharma20 open or runningphase 4since May 26, 2016Aug 1, 2011none ahead
Biogen20 open or runningphase 4since Mar 14, 2014Jan 20, 2011none ahead
Chong Kun Dang Pharmaceutical20 open or runningphase 1since Dec 20, 2010Dec 20, 2010none ahead
GlaxoSmithKline20 open or runningphase 1since May 2, 2013May 2, 2013none ahead
Merck20 open or runningphase 1since Nov 10, 2009Nov 10, 2009none ahead
PLx Pharma20 open or runningphase 2since Mar 10, 2009Mar 10, 2009none ahead
Azidus Brasil10 open or runningphase 3since Nov 12, 2009Nov 12, 2009none ahead
celonova-biosciences-inc10 open or runningno phasesince Aug 19, 2014Aug 19, 2014none ahead
Cordis10 open or runningphase 4since Aug 6, 2009Aug 6, 2009none ahead
Egymedicalpedia11 open or runningno phasesince Feb 7, 2024Feb 7, 2024none ahead
fertility-center-of-las-vegas11 open or runningphase 4since Nov 10, 2023Nov 10, 2023none ahead
GC Biopharma10 open or runningphase 4since May 16, 2019May 16, 2019none ahead
Hamad Medical10 open or runningphase 4since Mar 23, 2020Mar 23, 2020none ahead
Laboratorios Silanes S.A. de C.V.10 open or runningphase 1since Feb 24, 2026Feb 24, 2026none ahead
new-haven-pharmaceuticals-inc10 open or runningphase 1since Feb 11, 2015Feb 11, 2015none ahead
Novartis10 open or runningphase 4since Nov 23, 2010Nov 23, 2010none ahead
Otsuka10 open or runningphase 1since Sep 15, 2015Sep 15, 2015none ahead
Regeneron Pharmaceuticals10 open or runningno phasesince Sep 15, 2022Sep 15, 2022none ahead
rhoshan-pharmaceuticals-inc10 open or runningphase 1since Dec 18, 2025Dec 18, 2025none ahead
vectura-inc10 open or runningphase 1since Nov 1, 2022Nov 1, 2022none ahead
vita-green-health-products-co-ltd10 open or runningphase 1since Mar 4, 2021Mar 4, 2021none ahead

Also a collaborator on its studies: cardialysis-b-v, Terumo and clinlogix-llc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Aug 6, 2009.

  1. Oct 4, 2018Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT03698513 · 113 enrolled · United States
  2. May 16, 2019GC Biopharma's first study: phase 4 study in Mucocutaneous Lymph Node SyndromeNew to GC BiopharmaGC Biopharma · NCT04003844 · 45 enrolled · Korea, Republic of
  3. Jul 2, 2019Phase 1 study in BioequivalencePLx Pharma · NCT04008979 · 32 enrolled
  4. Aug 21, 2019No phase study in Heart FailureAbbott · NCT04069156 · 628 enrolled · United States, Australia, Austria and more
  5. Mar 23, 2020Hamad Medical's first study: phase 4 study in Ischemic StrokeNew to Hamad MedicalHamad Medical · NCT04330872 · 42 enrolled · Qatar
  6. Mar 4, 2021vita-green-health-products-co-ltd's first study: phase 1 study in Cardiovascular DiseasesNew to vita-green-health-products-co-ltdvita-green-health-products-co-ltd · NCT04792723 · 24 enrolled
  7. Sep 15, 2022Regeneron Pharmaceuticals's first study: no phase study in DiseaseNew to Regeneron PharmaceuticalsRegeneron Pharmaceuticals · NCT05546957 · 60 enrolled · United Kingdom
  8. Nov 1, 2022vectura-inc's first study: phase 1 study in Respiratory AspirationNew to vectura-incvectura-inc · NCT05625334 · 86 enrolled · United States
  9. Nov 10, 2023fertility-center-of-las-vegas's first study: phase 4 study in Infertility, FemaleNew to fertility-center-of-las-vegasfertility-center-of-las-vegas · NCT06133803 · 130 planned · United States
  10. Feb 7, 2024Egymedicalpedia's first study: no phase study in Pre-EclampsiaNew to EgymedicalpediaEgymedicalpedia · NCT06261203 · 250 planned · Egypt
  11. Oct 22, 2024Phase 1 study in BioequivalenceBayer · NCT06655194 · 38 enrolled · Mexico
  12. Dec 18, 2025rhoshan-pharmaceuticals-inc's first study: phase 1 study in HealthyNew to rhoshan-pharmaceuticals-incrhoshan-pharmaceuticals-inc · NCT07323680 · 40 enrolled · Czechia
  13. Feb 24, 2026Laboratorios Silanes S.A. de C.V.'s first study: phase 1 study in HealthyNew to Laboratorios Silanes S.A. de C.V.Laboratorios Silanes S.A. de C.V. · NCT07444164 · 24 enrolled · Mexico
  14. Jun 8, 2026Phase 1 study in Drug-drug InteractionBayer · NCT07652723 · 16 planned · United States

Ahead

  1. Mar 10, 2027Primary completion: phase 1 study in Drug-drug InteractionBayer · NCT07652723

TargetBeta

PTGS1 →PTGS2 →read by rule
“Cyclooxygenase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
AcetaminophenruleJohnson & Johnsonphase 4136
IbuprofenrulePfizerphase 4113
dexketoprofenruleMenarini Groupphase 48
SulfasalazineruleBristol-Myers Squibbphase 47
dexibuprofenruleaponia-laboratories-incphase 46
BenzydamineruleAngelini Pharmaphase 44
DipyroneruleHypera Pharmaphase 44
PiroxicamruleTaisho Pharmaceuticalphase 44
FlurbiprofenruleGlaxoSmithKlinephase 312

Studies

The newest 60 of 70 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07652723Drug-drug Interaction · United States1RecruitingBayerMar 10, 202716
NCT07444164Healthy · Mexico1CompletedLaboratorios Silanes S.A. de C.V.Jan 23, 202524
NCT07323680Healthy · Czechia1Completedrhoshan-pharmaceuticals-incJul 7, 202540
NCT06655194Bioequivalence · Mexico1CompletedBayerApr 6, 202538
NCT06261203Pre-Eclampsia · Egypt–RecruitingEgymedicalpediaJul 1, 2025250
NCT06133803Infertility, Female · United States4Recruitingfertility-center-of-las-vegasDec 15, 2024130
NCT05625334Respiratory Aspiration · United States1Completedvectura-incMar 9, 202386
NCT05546957Disease · United Kingdom–CompletedRegeneron PharmaceuticalsApr 6, 202360
NCT04792723Cardiovascular Diseases1UNKNOWNvita-green-health-products-co-ltdJul 1, 202124
NCT04330872Ischemic Stroke · Qatar4CompletedHamad MedicalJan 4, 202042
NCT04069156Heart Failure · United States, Australia, Austria and more–CompletedAbbottAug 10, 2023628
NCT04008979Bioequivalence1CompletedPLx PharmaJun 10, 200832
NCT04003844Mucocutaneous Lymph Node Syndrome · Korea, Republic of4CompletedGC BiopharmaNov 22, 201945
NCT03698513Healthy Volunteers · United States1CompletedBristol-Myers SquibbFeb 19, 2019113
NCT03225352Moderate Pain · United Kingdom1CompletedBayerOct 7, 201712
NCT03197779Thrombosis · United States1CompletedBristol-Myers SquibbFeb 2, 2016691
NCT03056703Pain · United States1CompletedBayerMar 201438
NCT02846532Thrombosis · United States, Argentina, Belgium and more3CompletedJohnson & JohnsonJul 16, 2020112
NCT02786979Diabetes Mellitus, Type 2 · China4TerminatedAstellas PharmaJan 2013190
NCT02554721Healthy · Germany1CompletedOtsukaMar 30, 201877
NCT02439190Thrombosis · United Kingdom1CompletedBristol-Myers SquibbMar 201642
NCT02394093Pharmacology, Clinical · United States1CompletedBayerMar 201530
NCT02370680Cardiovascular Diseases · United States1Completednew-haven-pharmaceuticals-incJul 201541
NCT02341638Thrombosis · United States1CompletedBristol-Myers SquibbSep 2015148
NCT02268773Healthy1CompletedBoehringer IngelheimMay 200027
NCT02262793Healthy1CompletedBoehringer IngelheimJul 200424
NCT02224235Angina, Stable · Finland–Terminatedcelonova-biosciences-incJun 20158
NCT02183688Migraine Disorders3CompletedBoehringer IngelheimJan 20031,889
NCT02090413Multiple Sclerosis, Relapsing-Remitting · Ireland, United Kingdom4CompletedBiogenFeb 2015241
NCT01847417Ulcer · India1CompletedGlaxoSmithKlineJul 1, 201324
NCT01847404Ulcer · India1CompletedGlaxoSmithKlineJun 28, 201324
NCT01830543Atrial Fibrillation · United States, Argentina, Australia and more3CompletedJohnson & JohnsonJul 28, 20162,124
NCT01776424Coronary Artery Disease · United States, Argentina, Australia and more3CompletedBayerJul 21, 201727,395
NCT01589978Coronary Artery Disease · United States4CompletedBoston ScientificAug 20142,681
NCT01552798Headache · United States3TerminatedBayerJun 4, 20129
NCT01500434Coronary Artery Disease · United States, Australia, Belgium and more3CompletedBoston ScientificMar 2011102
NCT01510327Coronary Artery Disease · United States, Japan3CompletedBoston ScientificFeb 201022
NCT01496261Coronary Artery Disease · Korea, Republic of1CompletedChong Kun Dang PharmaceuticalSep 201160
NCT01424332Pharmacodynamic and Pharmacokinetic Interaction · France1CompletedAstellas PharmaMar 200824
NCT01420094Toothache · United States3CompletedBayerSep 8, 2011510
NCT01361399Common Cold · Russian Federation, Ukraine3CompletedBayerMay 28, 20051,088
NCT01465009Common Cold · United Kingdom4CompletedBayer508
NCT01464983Headache · United Kingdom4CompletedBayer1,115
NCT01464944Respiratory Tract Infections · Russian Federation, Ukraine4CompletedBayer392
NCT01281111Healthy · United States1CompletedBiogenMar 18, 201156
NCT01663038Coronary Artery Disease · Korea, Republic of1CompletedChong Kun Dang PharmaceuticalJan 201160
NCT01248468Pain · United States4CompletedNovartisMar 2011752
NCT01227629Atrial Fibrillation · United States, Denmark, Sweden2CompletedBoehringer IngelheimNov 2004502
NCT01122602Drugs, Investigational · United States3CompletedBayerJul 29, 2010500
NCT01117636Drugs, Investigational · United States3CompletedBayerJul 7, 2010514
NCT01108588Healthy Volunteers1CompletedMerckAug 201015
NCT01081353Pharmacokinetics · United States1CompletedBayerMar 201026
NCT01072604Pharmacokinetics · United States1CompletedBayerAug 200930
NCT01033526Common Cold · Italy4CompletedBayer388
NCT01062360Common Cold · United States, Italy, Poland and more3CompletedBayerMay 14, 20071,016
NCT01028079Low Back Pain · Germany, United Kingdom3CompletedBayer338
NCT01012349Treatment of Episodic Tension Headache · Brazil3UNKNOWNAzidus BrasilMay 2011152
NCT01012219Hyperlipoproteinemia Type II1CompletedMerckMar 201036
NCT00963443Common Cold · United Kingdom3CompletedBayerMar 2012833
NCT00954707Coronary Artery Disease · United States4UNKNOWNCordisJan 20122,509

How it is read

Names in the registry

  • “Aspirin”, 25 entries
  • “dabigatran with ASA”, 6 entries
  • “ASA”, 5 entries
  • “Acetylsalicylic acid (Aspirin, BAY1019036)”, 5 entries
  • “Acetylsalicylic acid (Aspirin, BAYE4465)”, 5 entries

Codes read as this program: BAY1019036.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.